GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Suven Life Sciences Ltd

Suven Life Sciences Allots 1.85 Cr Equity Shares on Preferential Basis

FUNDRAISE ▲ Positive Development LOW RISK
📅 Filed on BSE: 08 Jul 2026, 12:57 PM IST  ·  BSE ID: bf356882-ec75-4861-92a5-792f1867a8b8
View Original BSE Filing (PDF)
💡
In Simple Terms
Suven Life Sciences converted warrants into new shares, raising over Rs. 248 Crore and increasing its paid-up capital.
🤖 AI Summary
  • Suven Life Sciences approved allotment of 1,85,70,133 equity shares on preferential basis.
  • Shares issued upon conversion of fully paid warrants at Rs. 134 per share.
  • Fundraising totals Rs. 248,83,97,822 from these warrant conversions.
  • Board approved re-appointment of Independent Director for a second five-year term.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Equity Shares Allotted
1,85,70,133
Issue Price per Share
Rs. 134/-
Total Consideration Received
Rs. 248,83,97,822/-
Pre-issue Paid-up Capital
26,39,92,553/-
Post-issue Paid-up Capital
28,25,62,686/-
🏢 How This Affects the Company
📈
Business Impact
The preferential allotment of equity shares enhances the company's capital base.
💰
Financial Impact
The company received Rs. 248,83,97,822 as consideration, increasing its paid-up equity share capital to Rs. 28,25,62,686.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders regarding this allotment.
👤
Who Is Affected
Existing shareholders' proportionate ownership may be diluted due to the issuance of new equity shares.
🔍
Management Signal
Management is actively utilizing capital instruments like warrants to raise funds and strengthen the company's equity base.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Disclosure on Singapore subsidiary incorporation details.
Outcome of AGM regarding re-appointment of Independent Director.
Next quarterly financial results announcement for performance updates.
LOW RISK Standard preferential allotment; no immediate adverse risks flagged in the filing.
💡 Investor Takeaway
Suven Life Sciences raised Rs. 248,83,97,822 by allotting 1,85,70,133 equity shares at Rs. 134 each upon warrant conversion, increasing paid-up capital to Rs. 28,25,62,686.
⚖️ Strengths & Concerns

✅ Positives

  • Successfully raised Rs. 248,83,97,822 through preferential allotment of 1,85,70,133 equity shares.
  • Strengthened paid-up equity share capital by Rs. 1,85,70,133 from Rs. 26,39,92,553 to Rs. 28,25,62,686.
❓ Frequently Asked Questions
How many equity shares did Suven Life Sciences allot on preferential basis?
Suven Life Sciences allotted 1,85,70,133 equity shares on a preferential basis upon conversion of fully paid warrants.
What is the total amount raised by Suven Life Sciences from this preferential allotment?
The company received a total consideration of Rs. 248,83,97,822/- from the allotment of these equity shares.
At what price were the new equity shares issued?
The new equity shares were issued at an issue price of Rs. 134/- per share on a preferential basis.
What is the post-issue subscribed and paid-up capital of Suven Life Sciences?
Post-issue, the subscribed and paid-up capital stands at Rs. 28,25,62,686/-.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.